A single-center retrospective study in China found a significant association between pain duration and intensity in patients ...

The approval was based on data from the randomized, placebo-controlled, double-blind, phase 3 RATIONALE-305 trial.

She started chemotherapy and after a couple of treatments, she developed neuropathy… a side effect that causes numbness, ...

The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy to treat unresectable or metastatic, HER2-, PD-L1+ gastric or GEJ adenocarcinoma.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) ...